|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.33/-0.39
|
企業價值
225.97M
|
資產負債 |
每股賬面淨值
0.88
|
現金流量 |
現金流量率
--
|
損益表 |
收益
18.91M
|
每股收益
0.04
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比較之報價最少15分鐘延遲
業務概覽
|
|||
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. |